COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
NCT ID: NCT05075538
Last Updated: 2024-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
152 participants
INTERVENTIONAL
2021-12-01
2024-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
NCT04847050
Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients
NCT04854980
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
NCT04930055
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
NCT05054218
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
NCT04158583
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spikevax
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Comirnaty
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Spikevax bivalent Original/Omicron BA.1
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Spikevax bivalent Original/Omicron BA.4-5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Comirnaty Original/Omicron BA.1
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Comirnaty Original/Omicron BA.4-5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Comirnaty Omicron XBB.1.5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Spikevax Omicron XBB.1.5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ECOG performance status ≤ 2
3. Subjects with histologically or cytologically confirmed cancer diagnosis (invasive solid tumour or haematological malignancy)
* undergoing active systemic cancer treatment at the time of the last dose (before ICF signature) of the anti-SARS-CoV-2 mRNA vaccine (such as chemotherapy, immunotherapy, targeted agents, endocrine therapy) in non-metastatic/curative setting or in metastatic/palliative setting
* or undergoing follow-up after confirmed cancer complete remission without active cancer treatment for the last 12 months at the time of the last dose (before ICF signature ) of the anti-SARS-CoV-2 mRNA vaccine.
4. Life expectancy \> 6 months
5. Subjects who received at least 2 doses of mRNA platform vaccination against SARS-CoV-2 as per local guidelines, with the last dose being given between 3 and 12 months prior to baseline assessment.
6. Urine/serum pregnancy test negative for all female subjects of childbearing potential within 7 days prior to subject enrolment.
7. Signed Informed Consent form (ICF) obtained prior to any study related procedure
8. Subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.
Exclusion Criteria
2. Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.
3. Subjects with active diagnosis of acute leukaemia.
4. Subjects treated with bone marrow transplant \< 90 days before received vaccination against SARS-CoV-2.
5. Subjects with a known history of HIV infection.
6. COVID-19 infection in the last 28 days prior to subject enrolment.
7. Subjects receiving prolonged and/or high doses of systemic immunosuppressive therapies including corticosteroids during the last 28 days before receiving first dose of vaccination against SARS-CoV-2 and up to subject enrolment.
8. Subjects who, for any reason, did not receive the 2nd dose of the anti-SARS-CoV-2 mRNA vaccine.
9. Subjects that received the 3rd dose of anti-SARS-CoV-2 mRNA vaccine prior to study entry. Exclusion criterion number 9 is only applicable for previous versions of the protocol and is not applicable from protocol version 3.0 and subsequent versions.
10. Subject that received any dose of non-mRNA anti-SARS-CoV-2 vaccine platform.
11. Subject with a known or suspected history of severe adverse reactions associated with a vaccine and/or with severe allergic reaction to vaccine components or anaphylaxis in the past.
12. Subjects who planned to receive any other licensed vaccines for other indications within 28 days prior to the first booster dose after ICF signature or who are planning to receive any other vaccine up to 14 days after the first booster dose of the mRNA anti-SARS-CoV-2 vaccine after ICF signature (28 days for live attenuated vaccines). For influenza vaccination, a shorter interval or simultaneous administration is acceptable.
13. Subjects who have planned to receive a booster dose after ICF signature but before the baseline assessment
14. Subjects who received COVID-19 pre-exposure prophylactic monoclonal antibodies or who have been treated with anti-SARS-CoV-2 monoclonal antibodies or COVID-19 convalescent plasma during the last 6 months before ICF signature.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Pharma AG
INDUSTRY
Jules Bordet Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Jules Bordet
Anderlecht, , Belgium
CHU UCL Namur Sainte-Elisabeth
Namur, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-003710-39
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
IJB-COVID-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.